Rep. Marjorie Taylor Greene Buys Amgen Inc. (NASDAQ:AMGN) Stock

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on September 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on September 11th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of iShares Bitcoin Trust ETF (NASDAQ:IBIT) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of Morgan Stanley (NYSE:MS) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of Duke Energy (NYSE:DUK) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of ASML (NASDAQ:ASML) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of CrowdStrike (NASDAQ:CRWD) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of Digital Realty Trust (NYSE:DLR) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of Morgan Stanley (NYSE:MS) on 8/28/2025.

Amgen Price Performance

AMGN stock traded up $2.21 during trading on Tuesday, reaching $276.18. The company’s stock had a trading volume of 713,697 shares, compared to its average volume of 2,774,851. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The company’s fifty day moving average is $288.42 and its 200-day moving average is $288.61. The company has a market capitalization of $148.68 billion, a P/E ratio of 22.56, a price-to-earnings-growth ratio of 2.37 and a beta of 0.49. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $335.88.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same quarter in the prior year, the company posted $4.97 earnings per share. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date was Friday, August 22nd. Amgen’s dividend payout ratio is presently 77.84%.

Hedge Funds Weigh In On Amgen

A number of hedge funds have recently added to or reduced their stakes in the stock. Wealth Preservation Advisors LLC bought a new position in shares of Amgen during the 1st quarter worth $25,000. First Pacific Financial boosted its stake in shares of Amgen by 304.5% during the first quarter. First Pacific Financial now owns 89 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 67 shares in the last quarter. CBIZ Investment Advisory Services LLC increased its holdings in Amgen by 1,214.3% during the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock valued at $29,000 after buying an additional 85 shares during the period. Legacy Investment Solutions LLC bought a new position in Amgen in the second quarter worth approximately $27,000. Finally, Activest Wealth Management lifted its holdings in Amgen by 3,433.3% during the first quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock worth $33,000 after buying an additional 103 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the business’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president directly owned 7,209 shares of the company’s stock, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.69% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on AMGN shares. William Blair reissued an “outperform” rating on shares of Amgen in a report on Tuesday, June 24th. UBS Group cut their price target on Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a report on Wednesday, August 6th. Bank of America lifted their price objective on Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research note on Friday. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Piper Sandler boosted their price target on shares of Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a research report on Monday, August 25th. Seven equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $309.70.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2026 election.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.